Guidelines for the management of intravascular catheter-related infections

Clinical Infectious Diseases

Volumn 32, Issue 9, 2001, Pages 1249-1272

  Mermel, L A ^a   Farr, B M ^a   Sherertz, R J ^a   Raad, I I ^a   O'Grady, N ^a   Harris, J S ^a   Craven, D E ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPHOTERICIN B; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; FLUCONAZOLE; GENTAMICIN; IMIPENEM; KETOCONAZOLE; LINEZOLID; MEROPENEM; NAFCILLIN; OXACILLIN; PSEUDOMONIC ACID; RIFAMPICIN; STREPTOKINASE; SULTAMICILLIN; TICARCILLIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIMICROBIAL THERAPY; BACTERIAL ENDOCARDITIS; BLOOD CULTURE; CATHETER INFECTION; CLINICAL TRIAL; COLONY FORMING UNIT; DRUG BIOAVAILABILITY; DRUG HYPERSENSITIVITY; GRAM STAINING; HUMAN; INTRAVASCULAR CATHETER; MINIMUM INHIBITORY CONCENTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; ULTRASOUND;

ANTI-INFECTIVE AGENTS; BACTEREMIA; CATHETERIZATION, CENTRAL VENOUS; CATHETERIZATION, PERIPHERAL; CATHETERS, INDWELLING; CROSS INFECTION; EQUIPMENT CONTAMINATION; EVIDENCE-BASED MEDICINE; FUNGEMIA; HUMANS;

EID: 0035341173     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/320001     Document Type: Review

References (210)

1. Purpose of quality standards for infectious diseases. Infectious Diseases Society of America
2. Infections due to infusion therapy
3. Guideline for prevention of intravascular-device-related infections
4. Nosocomial infection rates in adult and pediatric intensive care units in the United States
5. Diagnosis and management of infections of implantable devices used for prolonged venous access
6. Diagnosis of triple-lumen catheter infection: Comparison of roll plate, sonification, and flushing methodologies
7. Nosocomial bloodstream infection in critically ill patients: Excess length of stay, extra costs, and attributable mortality
8. Case fatality rate for catheter-related bloodstream infections (CRSBI): A meta-analysis
9. Changes in the spectrum of organisms causing bacteremia and fungemia in immunocompromised patients due to venous access devices
10. Diagnosis of vascular catheter-related bloodstream infection: A meta-analysis
11. Diagnosis of central venous catheter-related sepsis: Critical level of quantitative tip cultures
12. A semiquantitative culture method for identifying intravenous catheter-related infections
13. Infectious complications of Swan-Ganz pulmonary artery catheters and peripheral arterial catheters
14. Rapid diagnosis of central-venous-catheter-related bloodstream infection without catheter removal
15. Clinical utility of blood cultures drawn from indwelling central venous catheters in hospitalized patients with cancer
16. Blood cultures III
17. Evaluation of central venous catheter sepsis by differential quantitative blood culture
18. Earlier positivity of central venous versus peripheral blood cultures is highly predictive of catheter related sepsis
19. Diagnosis of catheter-related bacteremia: A prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures
20. Evaluation of culture techniques for diagnosis of catheter-related sepsis in critically ill patients
21. Diagnosis of catheter-related infections
22. Catheter-related sepsis in patients on intravenous nutrition: A prospective study of quantitative catheter cultures and guidewire changes for suspected sepsis
23. Prospective study of catheter replacement and other risk factors for infection of hyper-alimentation catheters
24. Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia
25. Proposed modifications to the Duke Criteria for the diagnosis of infective endocarditis
26. Recurrent Staphylococcus aureus bacteremia
27. Cost-effectiveness of trans-esophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia
28. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: Experience in 103 patients
29. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: A study of 55 cases and review
30. Positive intravenous line tip cultures as predictors of bacteremia
31. Consequences of intravascular catheter sepsis
32. Intravascular-catheter-related infections
33. Epidemiologic and microbiologic features of nosocomial bloodstream infection (NBSI) implicating a vascular catheter source: A case-control study of 85 vascular catheter-related and 101 secondary NBSIs
34. Staphylococcus aureus bacteremia in patients with Hickman catheters
35. Conventional and nonconventional modes of vancomycin administration to decontaminate the internal surface of catheters colonized with coagulase-negative staphylococci
36. A new approach to the management of Broviac catheter infection
37. Antibiotic lock technique is an effective treatment of bacterial catheter related sepsis during parenteral nutrition
38. Long term follow-up of patients with catheter related sepsis (CRS) treated without catheter removal
39. Successful treatment of haemodialysis catheter-related sepsis without catheter removal
40. Diagnosis and conservative management (CM) of infection related to long term venous catheterization (CI) in AIDS patients
41. Treatment of Hickman catheter sepsis using antibiotic lock technique
42. Elimination of intraluminal colonization by antibiotic lock in silicone vascular catheters
43. Morbidity associated with long-term use of totally implantable ports in patients with AIDS
44. Five years' experience with the Quinton Permcath for vascular access
45. Evaluation of culture techniques for identification of catheter-related infection in hemodialysis patients
46. Successful treatment of Pseudomonas paucimobilis haemodialysis catheter-related sepsis without catheter removal
47. Septicemia in long-term jugular hemodialysis catheters: Eradicating infection by changing the catheter over a guide wire
48. Outcome and complications of temporary haemodialysis catheters
49. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteremia in hemodialysis patients
50. Efficacy of mupirocin nasal ointment in eradicating Staphylococcus aureus nasal carriage in chronic hemodialysis patients
51. The efficacy of mupirocin ointment and chlorhexidine body scrubs in the eradication of nasal carriage of Staphylococcus aureus among patients undergoing long-term hemodialysis
52. Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment
53. Rapid diagnosis of intravascular catheter-associated infection by direct gram staining of catheter segments
54. Ultrastructural analysis of indwelling vascular catheters: A quantitative relationship between luminal colonization and duration of placement
55. Impact of chlorhexidine-silver sulfadiazine-impregnated central venous catheters on in vitro quantitation of catheter-associated bacteria
56. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: A randomized, controlled trial
57. Quantitative culture of intravenous catheters and other intravascular inserts
58. Three-year experience with sonicated vascular catheter cultures in a clinical microbiology laboratory
59. Guidelines for meta-analyses evaluating diagnostic tests
60. Value of differential quantitative blood cultures in the diagnosis of catheter-related sepsis
61. A prospective randomized double-blind trial of bolus urokinase in the treatment of established Hickanan catheter sepsis in children
62. A prospective randomized trial of urokinase as an adjuvant in the treatment of proven Hickman catheter-sepsis
63. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: A study of 55 cases and review
64. Experimental endocarditis I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart
65. The clinical impact of culturing central venous catheters
66. The positive predictive value of isolating coagulase-negative staphylococci from blood cultures
67. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: Two-week combination therapy
68. Staphylococcus epidermidis and other coagulase negative staphylococci
69. The efficacy of rifampin as adjunctive therapy in selected cases of staphylococcal endocarditis
70. Antibiotic therapy of experimental Staphylococcus epidermidis endocarditis
71. Staphylococcus epidermidis prosthetic valve endocarditis: Microbiological and clinical observations as guide to therapy
72. Therapy for experimental endocarditis due to Staphylococcus epidermidis
73. Catheter-associated infections caused by coagulase-negative staphylococci: Clinical and biological aspects
74. Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home
75. Staphylococcus aureus bacteremia: Minimal effective therapy and unusual infectious complications associated with arterial sheath catheters
76. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: Experience with 244 patients
77. Therapeutic approaches in patients with candidemia: Evaluation in a multicenter prospective observational study
78. Recommendations for preventing the spread of vancomycin resistance
79. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug abusers
80. Slow response to vancomycin or vancomycin plus rifampin therapy among patients with methicillin-resistant Staphylococcus aureus
81. Complications associated with Staphylococcus aureus bacteremia
82. Prospective study of infections in indwelling central venous catheters using quantitative blood cultures
83. Incidence and management of catheter-related sepsis in patients receiving home parenteral nutrition
84. Cure of implantable venous port-associated bloodstream infections in pediatric hematology-oncology patients without catheter removal
85. Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: Increasing incidence of catheter-related infections
86. Nosocomial bacteremia due to Acinerobacter baumannii: Clinical features, epidemiology, and predictors of mortality
87. Killing of non-growing and adherent Escherichia coli determines drug efficacy in device-related infections
88. In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa
89. Effect of antibiotics on non-growing planktonic cells and biofilms of Escherichia coli
90. Miscellaneous organisms
91. Catheter-related infections due to gram-negative bacilli
92. Unusual organisms causing intravenous line infections in compromised hosts. I. Bacterial and algal infections
93. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
94. Practice guidelines for the treatment of candidiasis
95. Intravascular catheter exchange and duration of candidemia
96. Intravascular device-related infections in critically ill patients
97. International conference for the development of a consensus on the management and prevention of severe candidal infections
98. Preliminary results treating persistent central venous catheter infections with the antibiotic lock technique in pediatric patients
99. Malassezia furfur catheter infection cured with antibiotic lock therapy
100. Human infections due to Malassezia spp.
101. Catheter-related Malassezia furfur fungemia in immunocompromised patients
102. Central venous septic thrombophlebitis: The role of medical therapy
103. Candida septic thrombosis of the great central veins associated with central catheters
104. Case report: Treatment of Silastic catheter-induced central vein septic thrombophlebitis
105. Catheter-related septic central venous thrombosis: Current therapeutic options
106. Nosocomial blood-borne infection secondary to intravascular devices
107. Septic thrombosis of the maxillary and subclavian veins caused by a peripherally inserted central venous catheter
108. Septic endarteritis due to intra-arterial catheters for cancer chemotherapy. I. Evaluation of an outbreak. II. Risk factors, clinical features and management. III. Guidelines for prevention
109. Infected radial artery pseudoaneurysms occurring after percutaneous cannulation
110. Candidal suppurative peripheral thrombophlebitis
111. Candidal suppurative peripheral thrombophlebitis: Recognition, prevention, and management
112. Catheter-associated septic thrombophlebitis
113. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms
114. Prosthetic valve endocarditis resulting from nosocomial bacteremia: A prospective, multicenter study
115. Hospital acquired native valve endocarditis: Analysis of 22 cases presenting over 11 years
116. Hospital-acquired infectious endocarditis not associated with cardiac surgery: An emerging problem
117. Hospital-acquired infective endocarditis
118. Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis
119. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis: A randomized, controlled trial
120. Fungal endocarditis: A report on seven cases and a brief review
121. Subclavian hemodialysis catheter infections
122. Infection of hemodialysis catheters: Incidence and mechanisms
123. A prospective study of the mechanism of infection associated with hemodialysis catheters
124. Incidence and type of infection occurring in 445 chronic hemodialysis patients
125. High incidence of subclavian dialysis catheter bacteremias
126. Use of Dacron cuffed silicone catheters as long-term hemodialysis access
127. Septicemia in patients on chronic hemodialysis
128. Changing subclavian hemodialysis cannulas to reduce infection
129. Central venous access for hemodialysis using the Hickman catheter
130. Prospective evaluation of a Dacron cuffed hemodialysis catheter for prolonged use
131. Prevention of hemodialysis subclavian vein catheter infections by topical povidone-iodine
132. Staphylococcus aureus carriage rate of patients receiving long-term hemodialysis
133. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis
134. Skin and skin structure infection in the patient at risk: Carrier state of Staphylococcus aureus
135. Nasal and cutaneous flora among hemodialysis patients and personnel: Quantitative characterization and pattern of staphylococcal carriage
136. Infection rates of Broviac-Hickanan catheters and implantable venous devices
137. Broviac catheter-related bacteremia in oncology patients
138. Hickman catheter infections in patients with malignancies
139. Management of fever in patients with central vein catheters
140. Broviac catheter sepsis: The natural history of an iatrogenic infection
141. Management of septic complications associated with Silastic catheters in childhood malignancy
142. In situ management of confirmed central venous catheter-related bacteremia
143. The incidence of first Hickman catheter-related infection and predictors of catheter removal in cancer patients
144. Outpatient management of Hickman catheter sepsis
145. Indwelling venous access catheters in patients with acute leukemia
146. A modified right atrial catheter for access to the venous system in marrow transplant recipients
147. Occlusion and infection in Broviac catheters during intensive cancer therapy
148. Antibacterial activity, of teicoplanin and vancomycin in combination with rifampicin, fusidic acid, or fosfomycin against staphylococci on vein catheters
149. In vitro and in vivo effect on antibiotics on catheters colonized by staphylococci
150. Activity of eight antibacterial agents on Staphylococcus epidermidis attached to Teflon catheters
151. In vitro activity of vancomycin and teicoplanin against Staphylococcus epidermidis colonizing catheters
152. Effect of poly-urethane catheters and bacterial biofilms on the in-vitro activity of antimicrobials against Staphylococcus epidermidis
153. Pathogenesis of vascular catheter-related infections
154. Antibiotic-lock technique: A new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients
155. Quantitative blood cultures for diagnosis and management of catheter-related sepsis in pediatric hematology and oncology patients
156. Antibiotic lock technique
157. Antibiotic lock treatment (ALT): Impact on catheter salvage and cost savings
158. Limited efficacy of antibiotic lock techniques (ALT) in catheter related bacteremia of totally implanted ports (TIP) in HIV infected and oncologic patients
159. Study of serum kinetics of vancomycin during the "antibiotic-lock" technique [in French]
160. Stability of antibiotics in heparin at 37°C: Toward antibiotic locks for central venous catheter related infections
161. Nosocomial septicemia due to multiply antibiotic-resistant Staphylococcus epidermidis
162. Coagulase-negative staphylococcal bacteremia in patients receiving immunosuppressive therapy
163. Staphylococcus epidermidis bacteremia associated with vascular catheters: An important cause of febrile morbidity in hospitalized patients
164. Infections associated with subclavian Uldall catheters
165. Nosocomial coagulase-negative staphylococcal infections in bone marrow transplantation recipients with central vein catheter
166. The changing patterns of bacterial endocarditis
167. Infective endocarditis in the antibiotic era
168. Treatment of bacterial endocarditis
169. Prospective study of 114 consequences episodes of Staphylococcus aureus bacteremia
170. Staphylococcus aureus bacteremia: Current clinical patterns
171. Therapy of Staphylococcus aureus bacteremia associated with a removable focus of infection
172. Clinical value teichoic acid antibody titers in the diagnosis and management of the staphylococcemias
173. Short-course therapy for catheter-associated Staphylococcus aureusbacteremia
174. Short course therapy of catheter related Staphylococcus aureus bacteremia: A meta-analysis
175. Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS related complex
176. Staphylococcus aureus bacteremia and endocarditis
177. Severe staphylococcal infections: A randomized trial comparing quinolone + rifampin (iv then po) with conventional iv therapy
178. Treatment of right sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofioxacin and rifampicin
179. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy
180. Pharmacokinetics and metabolism of rifampin in humans
181. Rifamycins
182. Venous catheter-associated candidemia
183. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study
184. Outcome of treatment of candidemia in children whose central catheters were removed or retained
185. Candidemia in children with central venous catheters: Role of catheter removal and amphotericin B therapy
186. Vascular catheter-associated fungemia in patients with cancer: Analysis of 155 episodes
187. Treatment of Hickman catheter-related candidemia without removing the catheter
188. Prognosis and outcome of candidemia in cancer patients
189. Neonatal nosocomial infections
190. Catheter sepsis: The central venous line Achilles' heel
191. The CCSG prospective study of venous access devices: An analysis of insertions and causes for removal
192. The management of central venous catheter infections
193. Management of catheter related infections in pediatric patients
194. Intravenous access in infants and children
195. National nosocomial infection surveillance (NNIS) report, data summary from January 1992-April 2000
196. Nosocomial infections among neonates in high-risk nurseries in the United States
197. Nosocomial infections
198. Coagulase-negative staphylococcal bacteremia in the changing neonatal intensive care unit population: Is there an epidemic?
199. Central venous catheter infections
200. Prospective analysis of urokinase in the treatment of catheter sepsis in pediatric hematology-oncology patients
201. Successful treatment of Candida infected caval thrombus in critically ill infants by low dose streptokinase infusion
202. Suppurative thrombophlebitis in children: A ten-year experience
203. Nosocomial fungemia in a normal host
204. Quantitative bacteriology of peripheral venous cannulae in neonates
205. Serious complications of vascular catheter-related Staphylococcus aureus bacteremia in cancer patients
206. Candida albicans septic thrombosis of the right atrium is associated with a central venous catheter
207. Management of candidal thrombophlebitis of the central veins: Case report and review
208. Impact of a prevention strategy targeted at vascular-access care in incidence of infections acquired in intensive care